Results 11 to 20 of about 7,594,057 (369)
Cancer chemotherapy and biological response modifiers, 1990 In small cell lung cancer (SCLC) combination chemotherapy including agents such as etoposide, teniposide, cisplatinum, carboplatin, and vincristine, doxorubicin, and cyclophosphamide, or ifosfamide continues to be the back-bone of therapy. The epipodophyllotoxin derivatives together with cisplatin or carboplatin are being used increasingly as part of ...
H H, Hansen, M, Rørth
openaire +12 more sources
American Journal of Respiratory and Critical Care Medicine, 2021 Suzanne, Lareau +2 more
openaire +3 more sources
The blood proteome of imminent lung cancer diagnosis
Nature Communications, 2023 Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within ...
The Lung Cancer Cohort Consortium (LC3)
doaj +1 more source
Lung Cancer in the Netherlands [PDF]
Journal of Thoracic Oncology, 2021 Contains fulltext : 242608.pdf (Publisher’s version ) (Closed access)
Hendriks, L.E. +11 more
openaire +5 more sources
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
New England Journal of Medicine, 2022 BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde +28 more
semanticscholar +1 more source
Frontiers in Oncology, 2021 BackgroundTo investigate the differences in survival between lobectomy and sub-lobar resection for elderly stage I non-small-cell lung cancer (NSCLC) patients using the Surveillance, Epidemiology, and End Results (SEER) registry.MethodThe data of stage ...
Bo Zhang +12 more
doaj +1 more source
Cancer Medicine, 2023 Objective This study evaluated whether sublobar resection (sub‐L) is non‐inferior to lobectomy (L) for stage I (T1‐T2aN0M0) small cell lung cancer (SCLC) regarding long‐term overall survival (OS).
Ning Zhou +8 more
doaj +1 more source
Cancer Medicine, 2023 Background Poor prognosis is linked to peripheral blood levels of preoperative platelet‐lymphocyte ratio (PLR) and neutrophil‐lymphocyte ratio (NLR) in many advanced cancers. Nevertheless, whether the correlation exists in resected early‐stage cases with
Weibo Cao +9 more
doaj +1 more source